TelyRx Holdings Inc. faces a notable decline as market sentiment shifts.
TelyRx Holdings Inc. is experiencing a significant downturn, with its stock price dropping by 3.85% in today’s session to close at CA$2.50. This decline raises concerns among investors about the company’s short-term performance.
Investor takeaway: Investors should remain cautious as TelyRx navigates through a challenging market environment, particularly given its recent financial losses and lack of immediate positive news.
Advertisement
TelyRx Holdings Inc.
TELY.TO
TELY.TO
TelyRx Holdings Inc.
WealthAwesomeAdvertisement
Market cap
$69.10M
52W high
$4.25
52W low
$2.00
1W change
-3.70%
Analyst Price Targets
Based on analyst covering TELY
Wall Street analysts forecast TELY stock price to rise 130.8% over the next 12 months.
Consensus
BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$6.00
+130.8% Upside
Current Price
C$2.60
Last close
Analyst ratings and price targets are updated periodically. Not financial advice.
Advertisement
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on TELY's historical volatility
30-Day Vol
109.9%
Annualized
90-Day Vol
101.3%
Annualized
Trend (90d)
-50.0%
Annualized drift
90d Mean
C$2.17
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$2.45 | C$1.68 – C$3.58 |
| 60 trading days | C$2.31 | C$1.35 – C$3.95 |
| 90 trading days | C$2.17 | C$1.13 – C$4.19 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
TelyRx Holdings Inc. down 3.85% today
The stock's decline reflects broader market concerns and investor sentiment regarding its financial health.
Bull case
Despite the current slide, TelyRx has shown promising revenue growth in its recent quarterly results. This could indicate potential for recovery if the company can effectively manage its losses.
Bear case
The company's net loss of CA$4.7 million in the latest quarter, along with a rising adjusted EBITDA loss, suggests that TelyRx may struggle to maintain investor confidence in the near term.
Current Market Performance
Advertisement
TelyRx Holdings Inc. is facing a challenging market today, with its stock price falling by 3.85%. This decline comes after a recent quarterly report that highlighted an increase in revenue but also a significant net loss. Investors are likely weighing these factors as they consider the company's future prospects.
Financial Health Concerns
The latest financial results revealed that TelyRx’s net loss grew to CA$4.7 million, raising concerns about its profitability. While revenue increased to CA$19.4 million, the rising adjusted EBITDA loss signals potential operational challenges. Investors may want to keep a close eye on how the company addresses these issues moving forward.
Looking Ahead
With TelyRx Holdings Inc. now trading under the symbol TELY on the TSX, the company has entered a new phase following its reverse takeover. However, the current stock slide highlights the importance of monitoring both market sentiment and financial performance closely. Investors should consider the implications of today's decline as they evaluate their positions in TELY.TO.
Advertisement
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
